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Dissection of pleiotropic effects of missense mutations, rarelyinvestigated in inherited diseases, is fundamental to understand-ing genotype-phenotype relationships. Missense mutations
might impair mRNA processing in addition to protein properties. As a
model for hemophilia A, we investigated the highly prevalent F8
c.6046c>t/p.R2016W (exon 19) mutation. In expression studies exploit-
ing lentiviral vectors, we demonstrated that the amino acid change
impairs both Factor VIII (FVIII) secretion (antigen 11.0±0.4% of wild-
type) and activity (6.0±2.9%). Investigations in patients’ ectopic F8
mRNA and with minigenes showed that the corresponding nucleotide
change also decreases correct splicing to 70±5%, which is predicted to
lower further FVIII activity (4.2±2%), consistently with patients’ levels
(<1-5%). Masking the mutated exon 19 region by antisense U7snRNA
supported the presence of a splicing regulatory element, potentially
affected by several  missense mutations causing hemophilia A. Among
these, the c.6037g>a (p.G2013R) reduced exon inclusion to 41±3% and
the c.6053a>g (p.E2018G) to 28±2%, similarly to a variant affecting the
5’ splice site (c.6113a>g, p.N2038S, 26±2%), which displayed normal
protein features upon recombinant expression. The p.G2013R reduced
both antigen (7.0±0.9%) and activity (8.4±0.8%), while the p.E2018G
produced a dysfunctional molecule (antigen: 69.0±18.1%; activity:
19.4±2.3%). In conclusion, differentially altered mRNA and protein pat-
terns produce a gradient of residual activity, and clarify genotype-pheno-
type relationships. Data detail pathogenic mechanisms  that, only in
combination, account for moderate/severe  disease forms, which in turn
determine the mutation profile. Taken together we provide a clear exam-
ple of interplay between mRNA and protein mechanisms of disease that
operate in shaping many other inherited disorders.
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ABSTRACT
Introduction
It is widely accepted that mutations can have pleiotropic effects that define the
overall pathological phenotype.1,2 However, understanding in detail the contribu-
tion of each of these effects is complex and compromises clarification of geno-
type-phenotype relationships. Missense mutations are the second most common
cause of severe hemophilia A (HA)3 (http://www.eahad-db.org/; http://factorviii-
db.org/) and the most frequent cause of the rare coagulation factor deficiencies,4,5
as well as of other human diseases, and are known to impair several properties of
mutated proteins.6,7 However, coding sequences overlap with exonic pre-mRNA
splicing regulatory elements and thus missense changes may also affect pre-
mRNA processing.8,9
To quantitatively evaluate the interplay between the
effects of missense mutations on mRNA and protein
biosynthesis and their impact on HA coagulation pheno-
type, as a relevant model  we initially investigated the F8
p.R2016W (c.6046c>t) missense mutation (HGVS num-
bering; reference sequences NP_000123.1 and
NM_000132.3 for protein and cDNA, respectively).10 This
mutation in exon 19 is one of the most highly reported
amino acid substitutions (>60 patients), particularly in
Italy.11,12 It is suggested to affect splicing13 and candidate
to impair FVIII protein structure, but has never been char-
acterized. Here, we evaluated the potential pleiotropic
effects by extensive expression studies and dissected the
effects on FVIII protein secretion and activity as well as
on exon 19 definition. Intriguingly, several missense
mutations clustered in the p.R2016W region impacted on
each mechanism to a different extent, consistent with the
variable degree of HA severity. 
Methods
Lentiviral vectors and FVIII protein expression studies
Mutations were introduced by site-specific mutagenesis9 into
the codon-optimized human FVIII cDNA lacking B-domain
(coFVIII).14 The F8 exon 19 deleted cDNA fragment (FVIIIΔ19) was
made by overlapping PCR15 and subsequent cloning through the
MluI and SbfI restriction sites. 
The coFVIII variants were cloned in the lentivirus plasmid
pLNT backbone (Figure 1A) to produce lentiviruses (LV).14 CHO
cells16 were transduced with LV-rFVIII at MOI 2. Cells and media
were harvested 72 hours (h) post infection to evaluate lentiviral
copy number, FVIII antigen (ELISA) and chromogenic activity lev-
els, as described.14
Creation of F8 minigenes and splicing assays
The genomic cassette consisting of F8 exon 19 (117 bp) and the
surrounding intron 18 (343 nucleotides) and intron 19 (332
nucleotides) sequences  was amplified from DNA of a normal sub-
ject and cloned in the pTB vector17 through NdeI restriction sites
(Figure 2) within primers. Mutations were introduced by mutage-
nesis to create minigene variants. Expression vectors for the
U1snRNA and U7snRNA variants were created as described.18,19 
HepG2 or HEK293 cells were transfected9,20 with F8 minigenes
alone or equimolar amounts of pU1snRNA/pU7snRNAs to evalu-
ate exon 19 inclusion by RT-PCR with primers alpha 2,3 and Bra2.17
Evaluation of FVIII plasma levels and F8 splicing 
profile in HA patients
FVIII activity was evaluated by the 2-stage amidolytic assay
(Coamatic Factor VIII; Chromogenix, Lexington, MA, USA) and
the 1-stage coagulation assay as described.11 
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Figure 1. The splicing-defective F8 missense mutations differentially impair Factor VIII (FVIII) protein secretion and function. (A) Schematic representation (upper
part) of the lentiviral vector backbone harboring the codon-optimized cDNA of human FVIII lacking the B-domain (coFVIII) and sequence of the affected region and
of the investigated mutations (middle part). The alignment of FVIII sequence across species is reported (lower part) together with affected residues (red). (B) Secreted
FVIII antigen (upper) and co-factor activity (lower) levels of rFVIII variants expressed as % of rFVIIIwt. Secreted protein levels were normalized on virus copy number
per cell determined by qPCR.14 Results are reported as mean±Standard Deviation from three independent experiments. (C) Structure of the human FVIII (PDB: 2R7E).
Domain overview (A1-A2-A3-C1-C2 domains, inset) and interface between the A1 (blue) and A3 (white) domains (ribbon). The clustered residues under investigation
(HGVS numbering) are represented by ball and stick. The R2016 residue is shown in space-filling.    
A B
C
Ectopic mRNA was isolated from fresh leukocytes21 and evalu-
ated by RT-PCR using primers in F8 exon 17 and 22.
Studies of  patients’ sample were approved by the Review
Board of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico of Milan, and patients gave their written informed con-
sent.
Sequences of all primers used are listed in the Online
Supplementary Appendix.
Results
The impact of the F8 c.6046c>t/p.R2016W mutation on
FVIII protein and F8 mRNA splicing were extensively ana-
lyzed  using recombinant technologies. 
The R2016W substitution impairs both FVIII secretion
and function
So far, few HA-causing missense variants have been
characterized22-26 because of the very low secretion effi-
ciency of recombinant full-length rFVIII, which makes the
evaluation of the residual levels associated with variants
very difficult. To overcome this limitation, we exploited
the lentiviral-mediated delivery of the expression cassette
consisting of the codon-optimized FVIII cDNA lacking the
B domain (Figure 1A).14 In this experimental system, the
rFVIII-2016W missense variant (Figure 1B) was secreted in
medium at reduced levels (11.0±0.4% of rFVIIIwt) and, in
chromogenic assays, displayed an activity of 6.0±2.9%.
Although reduced, these FVIII activity values were slightly
higher than those measured in patients. The activity levels
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Table 1. Comprehensive overview of detrimental effects of in vivo and in vitro on F8 mRNA and FVIII protein expression.FVIII exon 19
Patients' features rFVIII/splicing DATA
Variants HA patients    FVIII activity (%) rFVIII activity ex19 inclusion Inferred FVIII activity (%)
HGVS Legacy AA n. Classification (%) (%) Classification
n.
p.G2013R 1994 1 <1 s 8.4±0.8 41±3 2.8-4.0 mo
p.R2016W 1997 61 <1-5 s/mo 6.0±2.9 70±5 2.0-6.7 mo/mi
p.E2018G 1999 7 1-4 mo 19.4±2.3 28±2 4.4-6.5 mo/mi
p.N2038S 2019 10 5-20 mo/mi 99.6±12.5 26±2 20.9-31.4 mi
Inferred Factor VIII (FVIII) activity levels, reported as a range, are calculated according to rFVIII activity corrected for the % of exon inclusion. FVIII activity levels in patients
affected by the p.R2016W mutation were measured by our group while those associated with the other mutations have been previously reported as referenced in the text,30-35
and as summarized in the HA mutation database (http://factorviii-db.org/). Severe (s), moderate (mo) or mild (mi) were defined as reported by Bolton-Maggs and Pasi.4 HGVS:
Human Genome Variation Society.
Figure 2. Features of the F8 minigene and of the sequences under investigation. Schematic representation (bottom) of the F8 exon 19 region cloned into the pTB
vector through the NdeI restriction sites (indicated). The sequences of the exon-intron boundary and of the engineered U1snRNA (U1 F8ex19) are reported together
with 3’ss and 5’ss scores (numbers) (splice site prediction by neural network; www.fruitfly.org). (Top) The region masked by the engineered U7 F8exon19 is magni-
fied. The investigated mutations are indicated as nucleotide and amino acid changes.
from1-stage clotting assays ranged from 1 to 6%
[mean±Standard Deviation (SD): 3.6±1.8%; median: 4%]
whereas those from chromogenic assays ranged from less
than 1 to 5%. The mean value of the latter cannot be esti-
mated because several patients display undefined values
below 1%. When the comparison was conducted for each
single patient, the chromogenic activity was, with the
above mentioned limitation, roughly half that of the clot-
ting one.
The c.6046c>t change promotes skipping of the poorly
defined F8 exon 19
The availability of RNA from leukocytes from a panel
(n=20) of HA patients affected by the F8 c.6046c>t muta-
tion prompted us to investigate the F8 mRNA splicing pat-
terns.27  The RT-PCR analysis showed, with the limitation
of studying ectopic expression, that the c.6046c>t change
alters splicing and decreases the proportion of correct tran-
scripts (74.1±14.5%) by inducing exon 19 skipping (Figure
3A and B, upper panels). To experimentally demonstrate
the causative nature of the c.6046c>t change and investi-
gate splicing mechanisms, we exploited F8 minigenes pre-
serving the authentic exon 19 nucleotide sequence (Figure
2, lower panel). Splicing assays in two different human
cell lines, HepG2 and HEK293, produced overlapping
results indicating that 93±2% of transcripts were correctly
spliced in the wild-type context (Figure 3A, lower panel).
Computational analysis showed that the 5’ and 3’ splice
sites (ss) defining exon 19 diverge significantly from the
consensus sequence, as witnessed by the low scores (5’ss,
0.55; 3’ss 0.14 vs. 1 of the consensus) (Figure 2, lower
panel), which might explain the observed exon skipping
rate (~7%). In this nucleotide context, the introduction of
the c.6046c>t mutation further decreased exon 19 inclu-
sion to 70% (Figure 3A, lower panel). To test the mecha-
nistic hypothesis that exon 19 is inherently prone to skip-
ping, we artificially strengthened exon 19 definition by
acting on the recognition of the 5’ss by the spliceosomal
U1snRNA, which is crucial in exon definition in the earli-
est splicing step.28 First, we optimized the authentic exon
19 5’ss by mutagenesis (high complementary 5’ss, 5’ssHC)
to make it fully-complementary to the wild-type
U1snRNA binding sequence, mimicking a perfect 5’ss.
Conversely, we challenged the F8 minigene with an engi-
neered U1snRNA (U1 F8ex19) designed to recognize the
authentic exon 19 5’ss (Figure 2, lower part). Both
approaches counteracted the effects of the  c.6046c>t
change  (Figure 3A, lower panel), indicating that the poor-
ly defined exon 19 strongly favored the variant’s patho-
genic role. 
The c.6046c>t mutation marks a splicing regulatory
region that is affected by several HA-causing missense
changes
To investigate whether the c.6046c>t change affects a
splicing regulatory element we took advantage of the
potent antisense approach based on the U7snRNA,29
which we designed (U7 F8exon19) to mask by base-pair-
ing the region including the variant (Figure 2, upper part).
Co-expression of the U7 F8exon19 (Figure 3A, lower
panel) induced complete exon skipping even in the wild-
type context, strongly suggesting the presence of a posi-
tive splicing regulatory element.
We therefore selected five missense variants reported as
causing HA clustered in the region covered by the U7
F8exon19 (Figure 2). Minigene assays demonstrated that
Pleiotropic effects of HA-causing mutations
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Figure 3. The c.6046c>t mutation as well as other adjacent missense changes promote exon 19 skipping differentially. (A) (Top) F8 splicing patterns in white blood
cells from a normal control (N) and from 6 representative hemophilia A (HA) patients (P1-6) affected by the c.6046c>t mutation. The RT-PCR was conducted with
primers in exons 17 and 22, and amplified fragments were separated on 2% agarose gel.  (Bottom) Splicing assays with the wild-type (wt) and the mutated
(c.6046c>t) minigenes. Effects of the antisense U7 F8ex19 (+) or the compensatory U1 F8ex19 (+) and of the strengthened 5’ss (5’ssHC) are shown. The RT-PCR
was conducted with primers alpha 2,3 and Bra2 in the pTB construct (see arrows in Figure 2). Amplified fragments  were separated on 2% agarose gel. Numbers
report the percentage of exon 19 inclusion measured in at least three independent experiments; expressed as mean ± Standard Deviation. The percentage of exon
19 inclusion was estimated by densitometric analysis of bands. n: normal; s: exon 19 skipped. (B) (Top) Comparison of the exon 19 inclusion rates measured in 20
HA patients affected by the c.6046c>t mutation (light gray column) and in HepG2 cells expressing F8 minigene variants (dark gray columns). (Bottom)
Representative example of splicing patterns of the selected missense variants. RT-PCR and analysis was conducted as in (A).
BA
two of them affected splicing (Figure 3B) and reduced
exon inclusion to 41±3% (p.G2013R/c.6037g>a)30 and
28±2% (p.E2018G/c.6053a>g).31-33 We extended the inves-
tigation to missense variants close to
(p.V2035A/c.6104t>c) or at (p.N2038S/c.6113a>g; -3 posi-
tion)32,34,35 the 5’ss, and only the latter reduced exon inclu-
sion (26±2%).
The splicing-defective F8 missense mutations 
differentially impair FVIII protein secretion and
function
To detail the impact of the underlying amino acid
changes on FVIII protein we expressed and characterized
the splicing-defective rFVIII missense variants. Results
from expression studies (Figure 1B) demonstrated a spec-
trum of secreted levels, from virtually normal (rFVIII-
2018G and rFVIII-2038S) to poor (rFVIII-2013R, 7.0±0.9%
of rFVIIIwt). Activity levels ranged from normal (rFVIII-
2038S) to significantly reduced (rFVIII-2018G, 19.4±2.3%;
rFVIII-2013R, 8.4±0.8%). The specific co-factor activity
(activity/antigen ratio) ranged from normal (rFVIII-2013R)
to 50% (rFVIII-2016W) or was significantly (rFVIII-2018G)
reduced, indicating dysfunctional features of the latter
FVIII variants. 
The study at the protein level was completed with the
expression of the in-frame transcript deriving from exon
19 skipping, clearly detectable in patients’ mRNA and
associated with all splicing-defective variants. The
rFVIIIΔ19 variant was not appreciably secreted, and,
therefore, did  not contribute to the FVIII protein levels.
Discussion
This study stems from the notion that amino acid and
splicing codes overlap36 and thus the frequent missense
changes, commonly considered only for the impact of the
amino acid substitution on protein biology, might also
have a detrimental effect on mRNA splicing. To provide
qualitative and quantitative insights into the potential
pleiotropic effect of missense mutations we chose to ana-
lyze the frequent p.R2016W/c.6046c>t variant reported to
cause HA.11,12 It has previously been suggested to alter
splicing13 and the amino change affects a partially (R2016)
conserved (Figure 1A, lower panel) residue that in the
FVIII structure (PDB: 2R7E)37  is surface exposed on the A3
domain at the interface with A1 domain (Figure 1C).
Previous studies have shown that amino acid substitu-
tions in this region have been shown to destabilize the
FVIIIa structure and impair FVIII function,38 with a discrep-
ancy in the functional activity values that were higher
when measured by 1-stage clotting assays than with the
chromogenic method.39-41 This activity profile was consis-
tent with that observed in plasma from several HA
patients bearing the F8 p.R2016W variant,  which strongly
supported an impact on the FVIII protein.   
Lentiviral-mediated expression of rFVIII led us to
demonstrate that the R2016W substitution differentially
impairs secreted (~11% of FVIIIwt) and functional (~6%)
protein levels, a finding that confirms the dysfunctional
features of the molecule. On the other hand, investigation
at the ectopic F8 mRNA level in several HA patients, and
through minigene assays, indicated that the corresponding
nucleotide change promotes exon 19 skipping.
Interestingly, the c.6046c>t change manifested the nega-
tive impact because of the weak context of exon 19, as
witnessed by the observation that its effect was removed
when placed in an artificially strengthened exon 19.
Moreover, the observation that masking the region by an
antisense U7snRNA induced exon-skipping revealed the
presence of a splicing regulatory element with enhancer
features not predicted by computational analysis.42 This
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Figure 4. Pleiotropic effects of F8 variants. Detrimental effects of variants on F8 splicing and on Factor VIII (FVIII) protein expressed as % reduction extent of wild-
type (wt) of correct transcripts (top: splicing impairment) or of co-factor activity (bottom: protein impairment).
was further supported by the identification of two adja-
cent  missense changes causing HA that remarkably
reduced exon inclusion (p.G2013R/c.6037g>a and
p.E2018G/c.6053a>g). Altogether these findings suggest
that splicing impairment by missense changes is largely
under-estimated. 
The identified splicing-defective missense variants
occur at residues that in the FVIII sequence alignment are
completely (G2013, E2018) conserved (Figure 1A, lower
panel), and in the FVIII structure37 are buried (G2013,
E2018) within the A3 domain at the interface with A1
domain (Figure 1C). Recombinant FVIII protein expression
demonstrated that they alter FVIII secretion and function
differentially. We also identified the p.N2038S/c.6113a>g
at the 5’ss (-3 position) that, as predicted, affected splicing.
However, the amino acid change at the poorly conserved
N2038 residue (Figure 1A) did not impact on FVIII protein
biology, a finding that supports the relevance of aberrant
splicing triggered by missense mutations.
The combination of detrimental effects on splicing and
protein observed in vitro (Figure 4) led us to infer FVIII
functional levels (Table 1) that are consistent, albeit slight-
ly over-estimated, with the FVIII activity measured in
patients affected by the mutations, in spite of  the consid-
erable biological variation in patients and some limitations
of the study. In particular, the exploitation of hybrid mini-
genes and the expression of FVIII molecules lacking the B
domain, necessary to appreciate the residual FVIII levels.
However, the 'improved' B-domainless features could
minimize the detrimental impact of amino acid substitu-
tions on intracellular FVIII biosynthesis, potentially rele-
vant for FVIII variants poorly secreted and functionally
normal (e.g. rFVIII-2013R). 
In summary, data clearly identify an F8 exonic region
that has evolved in relation to both mRNA maturation
(nucleotide splicing code) and protein (amino acid code)
constraints, a feature potentially shared with other exons
and with implications for the HA pathogenic mechanisms
and mutation pattern. 
For the first time, the combination of differentially
altered mRNA processing, FVIII biosynthesis and co-factor
activity was experimentally evaluated for clustered vari-
ants, and showed to substantially contribute to variably
significant FVIII deficiency. This accounts for a gradient of
residual FVIII activity that provides valuable information
as to how to interpret the HA coagulation phenotypes.
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